Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells

AS-ODN as effective purging agents

A. G. Wu, Shantaram S Joshi, W. C. Chan, P. L. Iversen, J. D. Jackson, A. Kessinger, Samuel Jay Pirruccello, W. G. Sanger, John G Sharp, D. J. Verbik, V. L. Whalen, M. R. Bishop

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We examined phosphorothioate oligodeoxyribonucleotides (ODNs) directed against bcr in exon 3 or exon 2, which are rearranged with exon 2 of abl (B3A2 and B2A2) at t(9;22) of chronic myelogenous leukemia (CML). Since these ODNs are designed to be CML cell specific, we studied their effects on the human CML cell line K562, which is known to have B3A2 rearrangement, and leukemic cells from patients, as well as normal hematopoietic stem cells in vitro. In vitro experiments were performed to determine a potential role of these two ODNs as ex vivo purging agents. Incubation of B3A2 antisense at 40, 80, and 120 μg/ml with K562 CML cells for 72 hours at 37°C resulted in 44% 56% and 63% reduction of CFU-L as compared to controls. In contrast, B3A2 sense and B2A2 antisense had no significant growth inhibitory effect on K562 cells. Incubation of B3A2 and B2A2 antisense ODNs at concentration of 80 μg/ml at 37°C for 36 hours with normal peripheral blood stem/progenitor cells (PBSC) resulted in 124% and 98% CFU-GM formation as compared to untreated controls, respectively. However, incubation of PBSC with B3A2 and B2A2 sense-ODNs resulted in a 22% and 44% reduction in CFU-GM, respectively. In order to determine the ex vivo purging effects of bcr-abl ODNs, the K562 cells were mixed with PBSC from normal donors at a ratio of 1:20 (CML:PBSC). The mixture of cells was then incubated with B3A2 antisense at 80 μg/ml for 36 hrs at 37°C. After incubation, no CML cells were detected by fluorescence in situ hybridization (FISH) as compared to untreated controls. These results were confirmed by RT-PCR using bcr-abl primers and mRNA isolated from the mixture of cells. Further, these results support the hypothesis that bcr-abl antisense ODNs are potentially effective agents for ex vivo purging of autologous stem cells before transplantation to eliminate/reduce the burden of leukemic cells. No significant toxicity to normal hematopoietic stem/progenitor cell population by the bcr-abl antisense ODNs was observed. Although unanticipated reductions in normal hematopoietic progenitor cells (CFU-GM) were observed with sense ODNs, no reduction in CFU-GM was observed with unrelated phosphorothioate ODN controls.

Original languageEnglish (US)
Pages (from-to)67-76
Number of pages10
JournalLeukemia and Lymphoma
Volume20
Issue number1-2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Antisense Oligonucleotides
Oligodeoxyribonucleotides
Myeloid Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Granulocyte-Macrophage Progenitor Cells
Antisense Oligodeoxyribonucleotides
Hematopoietic Stem Cells
Stem Cells
Exons
K562 Cells
Stem Cell Transplantation
Fluorescence In Situ Hybridization
Tissue Donors
Cell Line
Polymerase Chain Reaction
Messenger RNA
Peripheral Blood Stem Cells
Growth
Population

Keywords

  • Autologous stem cell transplant
  • B2A2
  • B3A2
  • Bcr-abl
  • Ex vivo purging agent

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells : AS-ODN as effective purging agents. / Wu, A. G.; Joshi, Shantaram S; Chan, W. C.; Iversen, P. L.; Jackson, J. D.; Kessinger, A.; Pirruccello, Samuel Jay; Sanger, W. G.; Sharp, John G; Verbik, D. J.; Whalen, V. L.; Bishop, M. R.

In: Leukemia and Lymphoma, Vol. 20, No. 1-2, 01.01.1995, p. 67-76.

Research output: Contribution to journalArticle

Wu, A. G. ; Joshi, Shantaram S ; Chan, W. C. ; Iversen, P. L. ; Jackson, J. D. ; Kessinger, A. ; Pirruccello, Samuel Jay ; Sanger, W. G. ; Sharp, John G ; Verbik, D. J. ; Whalen, V. L. ; Bishop, M. R. / Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells : AS-ODN as effective purging agents. In: Leukemia and Lymphoma. 1995 ; Vol. 20, No. 1-2. pp. 67-76.
@article{268722def988442d895b5a89319316d2,
title = "Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents",
abstract = "We examined phosphorothioate oligodeoxyribonucleotides (ODNs) directed against bcr in exon 3 or exon 2, which are rearranged with exon 2 of abl (B3A2 and B2A2) at t(9;22) of chronic myelogenous leukemia (CML). Since these ODNs are designed to be CML cell specific, we studied their effects on the human CML cell line K562, which is known to have B3A2 rearrangement, and leukemic cells from patients, as well as normal hematopoietic stem cells in vitro. In vitro experiments were performed to determine a potential role of these two ODNs as ex vivo purging agents. Incubation of B3A2 antisense at 40, 80, and 120 μg/ml with K562 CML cells for 72 hours at 37°C resulted in 44{\%} 56{\%} and 63{\%} reduction of CFU-L as compared to controls. In contrast, B3A2 sense and B2A2 antisense had no significant growth inhibitory effect on K562 cells. Incubation of B3A2 and B2A2 antisense ODNs at concentration of 80 μg/ml at 37°C for 36 hours with normal peripheral blood stem/progenitor cells (PBSC) resulted in 124{\%} and 98{\%} CFU-GM formation as compared to untreated controls, respectively. However, incubation of PBSC with B3A2 and B2A2 sense-ODNs resulted in a 22{\%} and 44{\%} reduction in CFU-GM, respectively. In order to determine the ex vivo purging effects of bcr-abl ODNs, the K562 cells were mixed with PBSC from normal donors at a ratio of 1:20 (CML:PBSC). The mixture of cells was then incubated with B3A2 antisense at 80 μg/ml for 36 hrs at 37°C. After incubation, no CML cells were detected by fluorescence in situ hybridization (FISH) as compared to untreated controls. These results were confirmed by RT-PCR using bcr-abl primers and mRNA isolated from the mixture of cells. Further, these results support the hypothesis that bcr-abl antisense ODNs are potentially effective agents for ex vivo purging of autologous stem cells before transplantation to eliminate/reduce the burden of leukemic cells. No significant toxicity to normal hematopoietic stem/progenitor cell population by the bcr-abl antisense ODNs was observed. Although unanticipated reductions in normal hematopoietic progenitor cells (CFU-GM) were observed with sense ODNs, no reduction in CFU-GM was observed with unrelated phosphorothioate ODN controls.",
keywords = "Autologous stem cell transplant, B2A2, B3A2, Bcr-abl, Ex vivo purging agent",
author = "Wu, {A. G.} and Joshi, {Shantaram S} and Chan, {W. C.} and Iversen, {P. L.} and Jackson, {J. D.} and A. Kessinger and Pirruccello, {Samuel Jay} and Sanger, {W. G.} and Sharp, {John G} and Verbik, {D. J.} and Whalen, {V. L.} and Bishop, {M. R.}",
year = "1995",
month = "1",
day = "1",
doi = "10.3109/10428199509054755",
language = "English (US)",
volume = "20",
pages = "67--76",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells

T2 - AS-ODN as effective purging agents

AU - Wu, A. G.

AU - Joshi, Shantaram S

AU - Chan, W. C.

AU - Iversen, P. L.

AU - Jackson, J. D.

AU - Kessinger, A.

AU - Pirruccello, Samuel Jay

AU - Sanger, W. G.

AU - Sharp, John G

AU - Verbik, D. J.

AU - Whalen, V. L.

AU - Bishop, M. R.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We examined phosphorothioate oligodeoxyribonucleotides (ODNs) directed against bcr in exon 3 or exon 2, which are rearranged with exon 2 of abl (B3A2 and B2A2) at t(9;22) of chronic myelogenous leukemia (CML). Since these ODNs are designed to be CML cell specific, we studied their effects on the human CML cell line K562, which is known to have B3A2 rearrangement, and leukemic cells from patients, as well as normal hematopoietic stem cells in vitro. In vitro experiments were performed to determine a potential role of these two ODNs as ex vivo purging agents. Incubation of B3A2 antisense at 40, 80, and 120 μg/ml with K562 CML cells for 72 hours at 37°C resulted in 44% 56% and 63% reduction of CFU-L as compared to controls. In contrast, B3A2 sense and B2A2 antisense had no significant growth inhibitory effect on K562 cells. Incubation of B3A2 and B2A2 antisense ODNs at concentration of 80 μg/ml at 37°C for 36 hours with normal peripheral blood stem/progenitor cells (PBSC) resulted in 124% and 98% CFU-GM formation as compared to untreated controls, respectively. However, incubation of PBSC with B3A2 and B2A2 sense-ODNs resulted in a 22% and 44% reduction in CFU-GM, respectively. In order to determine the ex vivo purging effects of bcr-abl ODNs, the K562 cells were mixed with PBSC from normal donors at a ratio of 1:20 (CML:PBSC). The mixture of cells was then incubated with B3A2 antisense at 80 μg/ml for 36 hrs at 37°C. After incubation, no CML cells were detected by fluorescence in situ hybridization (FISH) as compared to untreated controls. These results were confirmed by RT-PCR using bcr-abl primers and mRNA isolated from the mixture of cells. Further, these results support the hypothesis that bcr-abl antisense ODNs are potentially effective agents for ex vivo purging of autologous stem cells before transplantation to eliminate/reduce the burden of leukemic cells. No significant toxicity to normal hematopoietic stem/progenitor cell population by the bcr-abl antisense ODNs was observed. Although unanticipated reductions in normal hematopoietic progenitor cells (CFU-GM) were observed with sense ODNs, no reduction in CFU-GM was observed with unrelated phosphorothioate ODN controls.

AB - We examined phosphorothioate oligodeoxyribonucleotides (ODNs) directed against bcr in exon 3 or exon 2, which are rearranged with exon 2 of abl (B3A2 and B2A2) at t(9;22) of chronic myelogenous leukemia (CML). Since these ODNs are designed to be CML cell specific, we studied their effects on the human CML cell line K562, which is known to have B3A2 rearrangement, and leukemic cells from patients, as well as normal hematopoietic stem cells in vitro. In vitro experiments were performed to determine a potential role of these two ODNs as ex vivo purging agents. Incubation of B3A2 antisense at 40, 80, and 120 μg/ml with K562 CML cells for 72 hours at 37°C resulted in 44% 56% and 63% reduction of CFU-L as compared to controls. In contrast, B3A2 sense and B2A2 antisense had no significant growth inhibitory effect on K562 cells. Incubation of B3A2 and B2A2 antisense ODNs at concentration of 80 μg/ml at 37°C for 36 hours with normal peripheral blood stem/progenitor cells (PBSC) resulted in 124% and 98% CFU-GM formation as compared to untreated controls, respectively. However, incubation of PBSC with B3A2 and B2A2 sense-ODNs resulted in a 22% and 44% reduction in CFU-GM, respectively. In order to determine the ex vivo purging effects of bcr-abl ODNs, the K562 cells were mixed with PBSC from normal donors at a ratio of 1:20 (CML:PBSC). The mixture of cells was then incubated with B3A2 antisense at 80 μg/ml for 36 hrs at 37°C. After incubation, no CML cells were detected by fluorescence in situ hybridization (FISH) as compared to untreated controls. These results were confirmed by RT-PCR using bcr-abl primers and mRNA isolated from the mixture of cells. Further, these results support the hypothesis that bcr-abl antisense ODNs are potentially effective agents for ex vivo purging of autologous stem cells before transplantation to eliminate/reduce the burden of leukemic cells. No significant toxicity to normal hematopoietic stem/progenitor cell population by the bcr-abl antisense ODNs was observed. Although unanticipated reductions in normal hematopoietic progenitor cells (CFU-GM) were observed with sense ODNs, no reduction in CFU-GM was observed with unrelated phosphorothioate ODN controls.

KW - Autologous stem cell transplant

KW - B2A2

KW - B3A2

KW - Bcr-abl

KW - Ex vivo purging agent

UR - http://www.scopus.com/inward/record.url?scp=0029588277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029588277&partnerID=8YFLogxK

U2 - 10.3109/10428199509054755

DO - 10.3109/10428199509054755

M3 - Article

VL - 20

SP - 67

EP - 76

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -